Possible involvement of lipoxygenase products in human corpora lutea.
The present study was undertaken to determine the ability of cultured luteal cells from human corpora lutea to secrete progesterone (P4) and prostaglandins (PGs), and to assess the effects of the products of the lipoxygenase pathway on luteal P4 production. Luteal cells responded to human chorionic gonadotropin (hCG) with a significant increase (2- to 7-fold) in P4 production. Arachidonic acid significantly stimulated PGE2 synthesis by luteal cells in a dose-dependent manner. Both basal PGE2 production and the responsiveness to arachidonic acid were maintained for 8 days. In contrast, both PGF2 alpha and 6-keto-PGF1 alpha production abruptly declined as the culture proceeded. However, the addition of hCG did not further stimulate the accumulation of the 3 PGs assayed. In the subsequent experiment, 5-hydroxyeicosatetraenoic acid (5-HETE) and the reaction products of soybean lipoxidase of arachidonic acid (AA-LIP) were utilized for evaluating the involvement of the lipoxygenase pathway in luteolysis. The addition of 5-HETE dose-dependently inhibited P4 production by the cultured luteal cells. Although treatment with either arachidonic acid or lipoxidase alone had no effect on P4 production, AA-LIP significantly reduced P4 production in the presence or absence of hCG. These results suggest that the products of the lipoxygenase as well as of the cyclo-oxygenase pathway may be important in regulating the life span and function of human corpora lutea.
Yoshimura
Y
Y
Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Tokyo, Japan.
Nakamura
Y
Y
Oda
T
T
Yamada
H
H
Karube
M
M
Nanno
T
T
Ando
M
M
Ubukata
Y
Y
Koyama
N
N
Shiokawa
S
S
D000328:Adult; D016718:Arachidonic Acid / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology*; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology; D008084:Lipoxygenase / Q000502:physiology*; D011374:Progesterone / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D011460:Prostaglandins F / Q000096:biosynthesis
D006063:Chorionic Gonadotropin; D006893:Hydroxyeicosatetraenoic Acids; D011453:Prostaglandins; D011460:Prostaglandins F; D016718:Arachidonic Acid; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D011374:Progesterone; D015237:Dinoprost; D008084:Lipoxygenase; D015232:Dinoprostone